{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:35:53Z","timestamp":1791020153463,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors. For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies. IVIG now represents a standard therapeutic option for most antibody deficiencies. Routinely, IVIG is used in patients with X-linked agammaglobulinaemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class deficiency. In addition, IVIG is used extensively in the treatment of a wide variety of autoimmune disorders. IVIG is administered at distinct doses in the two clinical settings: whereas immunodeficient patients are treated with replacement levels of IVIG, patients with autoimmune and inflammatory diseases are administered with very high doses of IVIG. Several lines of experimental evidence gathered in the recent years suggest that the therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active role for IVIG, rather than a mere passive transfer of antibodies.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2011.04387.x","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T13:13:38Z","timestamp":1302009218000},"page":"2-5","source":"Crossref","is-referenced-by-count":110,"title":["Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy"],"prefix":"10.1093","volume":"164","author":[{"given":"S V","family":"Kaveri","sequence":"first","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9 872, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Equipe 16-Immunopathology and Therapeutic Immunointervention, Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"},{"name":"Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Maddur","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9 872, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Equipe 16-Immunopathology and Therapeutic Immunointervention, Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"},{"name":"Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hegde","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9 872, Paris, France"},{"name":"Universit\u00e9 de Technologie, Compi\u00e8gne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9 872, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Equipe 16-Immunopathology and Therapeutic Immunointervention, Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"},{"name":"Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bayry","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9 872, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Equipe 16-Immunopathology and Therapeutic Immunointervention, Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"},{"name":"Unit\u00e9 Mixte de Recherche-Sant\u00e9 872, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"2021122708481326400_b1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122708481326400_b2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tips.2004.04.002","article-title":"Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?","volume":"25","author":"Bayry","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"2021122708481326400_b3","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","article-title":"Control of early viral and bacterial distribution and disease by natural antibodies","volume":"286","author":"Ochsenbein","year":"1999","journal-title":"Science"},{"key":"2021122708481326400_b4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"2021122708481326400_b5","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708481326400_b6","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaci.2009.07.053","article-title":"Primary immunodeficiencies","volume":"125","author":"Notarangelo","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708481326400_b7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology \u2013 therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"2021122708481326400_b8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0481","article-title":"Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2021122708481326400_b9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","article-title":"Modulation of the cellular immune system by intravenous immunoglobulin","volume":"29","author":"Tha-In","year":"2008","journal-title":"Trends Immunol"},{"key":"2021122708481326400_b10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2021122708481326400_b11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","article-title":"What is the contents of the magic draft IVIg?","volume":"7","author":"Seite","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2021122708481326400_b12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","article-title":"The antiinflammatory IgG","volume":"359","author":"Kaveri","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708481326400_b13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.molimm.2004.07.046","article-title":"Therapeutic intravenous immunoglobulins","volume":"42","author":"Lemieux","year":"2005","journal-title":"Mol Immunol"},{"issue":"1","key":"2021122708481326400_b14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2009.04028.x","article-title":"6th International Immunoglobulin Symposium: poster presentations","volume":"158","author":"Fernandez-Cruz","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2021122708481326400_b15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins \u2013 understanding properties and mechanisms","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2021122708481326400_b16","doi-asserted-by":"crossref","first-page":"14210","DOI":"10.1073\/pnas.0402183101","article-title":"Natural antibodies sustain differentiation and maturation of human dendritic cells","volume":"101","author":"Bayry","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708481326400_b17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.amjmed.2005.06.028","article-title":"Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin","volume":"118","author":"Bayry","year":"2005","journal-title":"Am J Med"},{"key":"2021122708481326400_b18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2249.1999.00924.x","article-title":"In vivo modulation of cytokine synthesis by intravenous immunoglobulin","volume":"116","author":"Sewell","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2021122708481326400_b19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10238-009-0061-1","article-title":"In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency","volume":"10","author":"Artac","year":"2010","journal-title":"Clin Exp Med"},{"key":"2021122708481326400_b20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.autrev.2008.04.014","article-title":"Modulation of human dendritic cell maturation and function by natural IgG antibodies","volume":"7","author":"Elluru","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2021122708481326400_b21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"2021122708481326400_b22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.molmed.2005.06.005","article-title":"Common variable immunodeficiency: the immune system in chaos","volume":"11","author":"Bayry","year":"2005","journal-title":"Trends Mol Med"},{"issue":"10","key":"2021122708481326400_b23","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s10875-008-9182-7","article-title":"Autoimmune manifestations in common variable immunodeficiency","volume":"28","author":"Cunningham-Rundles","year":"2008","journal-title":"J Clin Immunol"},{"key":"2021122708481326400_b24","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood-2004-04-1325","article-title":"Common variable immunodeficiency is associated with defective functions of dendritic cells","volume":"104","author":"Bayry","year":"2004","journal-title":"Blood"},{"key":"2021122708481326400_b25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clim.2004.12.007","article-title":"Deficient IL-12 and dendritic cell function in common variable immune deficiency","volume":"115","author":"Cunningham-Rundles","year":"2005","journal-title":"Clin Immunol"},{"key":"2021122708481326400_b26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaut.2010.06.008","article-title":"The odd couple: a fresh look at autoimmunity and immunodeficiency","volume":"35","author":"Mackay","year":"2010","journal-title":"J Autoimmun"},{"key":"2021122708481326400_b27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708481326400_b28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jaut.2010.09.006","article-title":"Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies","volume":"36","author":"Bayry","year":"2011","journal-title":"J Autoimmun"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2011.04387.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/164\/Supplement_2\/2\/41909083\/j.1365-2249.2011.04387.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/164\/Supplement_2\/2\/41909083\/j.1365-2249.2011.04387.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:23:18Z","timestamp":1641054198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/164\/Supplement_2\/2\/6438941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":28,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2011,4,5]]},"published-print":{"date-parts":[[2011,4,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04387.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,6]]},"published":{"date-parts":[[2011,4,5]]}}}